Symbicort® Turbuhaler® now approved by Health Canada for use in mild persistent, moderate, or severe asthma

Monday, September 30, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

REFERENCES:

1.

AstraZeneca Canada Inc., Symbicort® Turbuhaler® (budesonide/formoterol) Product Monograph. Accessed September, 2019, available at: https://www.astrazeneca.ca/en/our-medicines.html

2.

O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018; 378: 1865-1876.

3.

Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018; 378: 1877-1887.

4.

O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. Supplementary Appendix. N Engl J Med. 2018; 378: 1865-1876.

5.

Statistics Canada, Catalogue no.82-625-X. Health Fact Sheets, Chronic Conditions, 2016. September 2017. https://www150.statcan.gc.ca/n1/pub/82-625-x/2017001/article/54858-eng.htm

6.

Public Health Agency of Canada. Report from the Canadian Chronic Disease Surveillance System: Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Canada, 2018. 

7.

Asthma Canada, Asthma Facts and Statistics, 2019. https://asthma.ca/wp-content/uploads/2019/02/Asthma-101.pdf Accessed August 2019.

8.

Olaguibel JM, Quirce S, Julia B, et al. Measurement of asthma control according to Global Initiative for Asthma guidelines: a comparison with the Asthma Control Questionnaire. Respir Res. 2012; 13: 50.

9.

Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014; 24: 14009.

10.

Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31: 143–78.

11.

Sastre J, Fabbri LM, Price D, et al. Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. World Allergy Organ J. 2016; 9: 13.

12.

AstraZeneca Pharmaceuticals. Data on file. Budesonide/formoterol: Annual Rate of Exacerbations Globally (ID:SD-3010-ALL-0017).

13.

Humbert M, Andersson TL, Buhl R. Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy. 2008; 63: 1567–80.

14.

Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur Respir J. 2000; 16: 802–7.

15.

Tattersfield AE, Postma DS, Barnes PJ, et al. on behalf of the FACET International Study Group. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med. 1999; 160: 594–9.

16.

Adams RJ, Fuhlbrigge A, Guilbert T, et al. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol. 2002; 110: 58–64.

17.

Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018; 11: 193–204.

18.

Cost Risk Analysis for Chronic Lung Disease in Canada, The Conference Board of Canada, Louis Theriault, Gregory Hermus, Danielle Goldfarb, Carole Stonebridge, Fares Bounajm, March 15 2012 http://www.conferenceboard.ca/elibrary/abstract.aspx?did=4585



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store